Regenxbio (RGNX) Stock Price Target 2026

The average analyst price target for Regenxbio is $23.67, 193.3% above the current price. Of 12 analysts, 10 rate it Buy and 2 Hold. Targets range from $12 to $50. The latest change came on Oct 5, 2026, when Mizuho initiated coverage of Regenxbio with an Outperform rating and a $22 price target.

The Average Analyst Price Target for Regenxbio is $23.67.

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

10Buy

2Hold

Consensus RatingOutperform# Analysts12Avg. Consensus PT$23.67Upside to Avg. PT+193.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Regenxbio Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	Mizuho	Graig Suvannavejh	Initiate	Outperform	$22
Aug 25, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$23→$21
Aug 25, 2026	Baird	Brian Skorney	PT Cut	Outperform	$32→$29
Aug 10, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$26→$23
Aug 7, 2026	Barclays	Eliana Merle	Downgrade	Overweight→Equal-Weight	$12
Jun 24, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$26
Jun 22, 2026	Baird	Brian Skorney	PT Raise	Outperform	$27→$32
Jun 22, 2026	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$17→$18
Jun 5, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$30→$26
May 15, 2026	B of A Securities	Geoff Meacham	PT Cut	Buy	$25→$14
May 15, 2026	Barclays	Gena Wang	PT Cut	Overweight	$37→$12
Mar 9, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$32→$30
Mar 6, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$18→$17
Feb 10, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$34→$32
Feb 10, 2026	Goldman Sachs	Paul Choi	PT Cut	Neutral	$14→$12
Feb 10, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$25→$18
Feb 10, 2026	Chardan Capital	Daniil Gataulin	PT Cut	Buy	$52→$50
Jan 29, 2026	Chardan Capital	Daniil Gataulin	Maintained	Buy	$52
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$40→$45
Dec 15, 2025	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$16→$20